Frontline gastric/GE junction cancer care now pairs chemo with checkpoint inhibitors for PD-L1 CPS≥1, improving survival and ...
Survival outcomes (mPFS 8.2 months; 12-month OS 80.8%) compare favorably with typical first-line chemo-immunotherapy ...
Regulatory review timelines shifted from March 29 to June 29, 2026, after FDA requested more time to assess CMC/manufacturing ...
Week-18 ORR equivalence was achieved for HD204 vs reference bevacizumab (48.7% vs 46.5%), with both risk ratio and risk ...
In patients with marginal zone lymphoma (MZL), venetoclax (Venclexta) plus ibrutinib (Imbruvica) demonstrated safety and ...
Relacorilant plus nab-paclitaxel achieved a 35% reduction in mortality risk with a 4.1-month median overall survival ...
Theriva Biologics has received FDA agreement on the core design elements of a pivotal Phase 3 trial evaluating zabilugene ...
Epigenetic drugs boost CD20/CD19 and T-cell activity, making bispecific antibodies hit lymphoma harder—now moving into ...
Nadofaragene firadenovec-vncg is the only FDA-approved nonreplicating intravesical gene therapy for high-risk ...
Discover how CAR-T, bispecifics and gene therapy reshape cancer care—and what clinics need for safe, reimbursable outpatient ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results